We offer a broad portfolio of CRISPR gene-edited iPSC cell lines that can be used to study CNS diseases beyond Parkinson’s and Alzheimer’s disease.

We work closely with you to design experiments, select the right cell lines, and adapt our models to your disease or mutation of interest, making sure the solutions fit your project and timelines.

These models can be applied to a range of CNS-related diseases, including neurodegenerative conditions such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

The lines are based on the same robust platform used for our Parkinson’s Disease and Alzheimer’s disease models, with differentiation and mutations tailored to the disease of interest.

Many of our iPSC lines have been thoroughly characterized and can be adapted to support your specific drug discovery questions. This makes them suitable for investigating genetic disease mechanisms, cellular function, and drug effects.

Our progranulin heterozygous and homozygous knock-out cell lines can, for example, be used to model frontotemporal dementia and ALS, with functional studies in iPSC-derived neurons, astrocytes, and microglia. Some of the read-outs could inform you about lysosomal function and progranulin release related to your drug candidates.